Cytokinetics Inc
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -25,451.1% | -4,428.1% | -15,509.8% | -39,884.7% | -21,922.2% | -387.4% | -8,335.5% | -192.1% | -5,552.9% | -803.4% | -751.5% | -500.8% | -782.8% | |
| 490.5% | 378.9% | 279.2% | 966.3% | 520.7% | 14.1% | 145.7% | 3.4% | 138.4% | 16.1% | 17.5% | 11.4% | 17.7% | |
| 4,951.3% | 1,165.5% | 2,588.3% | 9,888.4% | 5,476.5% | 155.1% | 1,491.4% | 41.2% | 1,585.5% | 171.8% | 157.0% | 111.9% | 179.4% | |
| 391.8% | 2,684.2% | -3,078.0% | 3,922.5% | 2,134.8% | 246.4% | -329.5% | -76.5% | 1,163.8% | -10.4% | -1.1% | -79.1% | -6.7% | |
| 58.2% | 4.6% | 210.1% | 769.1% | 530.2% | 7.6% | 358.7% | 6.2% | 483.2% | 31.8% | 30.6% | 13.6% | 35.6% | |
| 19,322.5% | -4,869.1% | 3,909.1% | -261,665.9% | -9,730.7% | 654.9% | 6,710.3% | 79.2% | -3,666.3% | -401.0% | 751.7% | -1,588.6% | -709.8% | |
| – | 891.9% | 3,536.8% | – | 3,672.6% | – | – | 21.6% | 1,101.8% | – | 58.6% | – | – | |
| – | – | – | – | -625.1% | -17.2% | -182.6% | -4.0% | 16,748.5% | -15.3% | -14.1% | -11.3% | 444.2% | |
| 14,343.7% | 10,095.7% | 12,430.1% | 329,723.3% | 739.7% | 14.1% | 301.1% | 117.6% | 17,069.5% | 623.5% | 40.1% | 2,484.4% | 1,750.0% | |
| 8,215.1% | 797.4% | 832.6% | 28,179.1% | -30,940.4% | 283.4% | -1,341.2% | 3.7% | 7,852.7% | -579.8% | 37.8% | 393.0% | 256.2% | |
| -25,509.3% | -4,432.7% | -15,299.8% | -40,653.8% | -22,452.5% | -395.0% | -8,694.2% | -198.3% | -6,036.1% | -835.2% | -782.2% | -514.4% | -818.4% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.